ClinicalTrials.gg
CompletedNCT00631488Updated Jan 2, 2017Results posted

A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

A Phase 2 interventional study of MK-0893 and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
85th of 197
146 · median 102
Started
2008
with 22 others
Phase 2
10 of 198
none open now
Registered
39th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 85th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 10 in phase 2, and was the 39th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will test the effectiveness and safety of treatment with MK-0893 in combination with other drugs commonly used to treat type 2 diabetes for a duration up to 13 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have Type 2 Diabetes Mellitus, with suboptimal glucose control, while either not on AHA (antihyperglycemic agent) therapy or on monotherapy or on low-dose combination therapy

Exclusion criteria

Exclusion Criteria:

  • Participants have a history of Type 1 Diabetes Mellitus
  • Participants taking insulin or thiazolidinediones (TZDs: peroxisome proliferator-activated receptor [PPAR]-gamma agonists)
  • Participants who have a to metformin or sitagliptin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    MK-0893 + Sitagliptin

    Drug: MK-0893 · Drug: Sitagliptin · Drug: Placebo for Metformin

  • Experimental
    MK-0893 + Metformin

    Drug: MK-0893 · Drug: Metformin · Drug: Placebo for Sitagliptin

  • Active comparator
    Sitagliptin + Metformin

    Drug: Sitagliptin · Drug: Metformin · Drug: Placebo for MK-0893

Interventions

  • Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).

  • Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).

    Also known as: JANUVIA™, MK0431

  • Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).

    Also known as: GLUCOPHAGE®

  • DrugPlacebo for MK-0893

    Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.

  • DrugPlacebo for Sitagliptin

    Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).

  • DrugPlacebo for Metformin

    Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).

06

What researchers measure

Primary outcomes

  1. Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels

    Time frame: BL, 4 weeks (end of double-blind treatment period)

Secondary outcomes

  1. Change From BL to Week 4 in Fasting Plasma Glucose (FPG)

    Time frame: BL, 4 weeks (end of double-blind treatment period)

  2. Change From BL to Week 4 in 2-hr Glucose Area Under The Curve (AUC)

    Time frame: BL, 4 weeks (end of double-blind treatment period)

  3. Change From BL to Week 4 in the 2-Hour Total GLP-1 Total AUC

    Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone that acts as a potent insulin secretegogue in response to nutrient ingestion and stimulates glucose disposition. The total AUC of Total GLP-1 levels was calculated from blood sample data measured after the morning meal.

    Time frame: BL, 4 weeks (end of double-blind treatment period)

  4. Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC

    GLP-1 is cleaved from proglucagon to form the active peptide GLP-1. The active form promotes suppression of glucagon secretion. The total AUC of Active GLP-1 levels was calculated from blood sample data measured after the morning meal.

    Time frame: BL, 4 weeks (end of double-blind treatment period)

07

Results

Posted Feb 17, 2012

Participant flow

Participant flow — Overall Study
MilestoneMK-0893 + SitagliptinMK-0893 + MetforminSitagliptin + Metformin
Started484949
Completed post-treatment period444747
Completed444747
Not completed422
Withdrew: Adverse event100
Withdrew: Lost to follow-up220
Withdrew: Physician decision101
Withdrew: Protocol violation001

Outcome measures

PrimaryChange From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels
Time frame:
BL, 4 weeks (end of double-blind treatment period)
Reported as:
Least squares mean · mg/dL
Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels
mg/dLMK-0893 + SitagliptinMK-0893 + MetforminSitagliptin + Metformin
Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels-85.7 ± 4.6-117.4 ± 4.6-99.6 ± 4.6
Statistical analysis
  • MK-0893 + Sitagliptin vs Sitagliptin + Metformin · Longitudinal Data Analysis · p = 0.002 · Mean difference (final values): 13.9 · 95% CI 5.2 to 22.7
  • MK-0893 + Metformin vs Sitagliptin + Metformin · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): -17.8 · 95% CI -26.5 to -9.2
SecondaryChange From BL to Week 4 in Fasting Plasma Glucose (FPG)
Time frame:
BL, 4 weeks (end of double-blind treatment period)
Reported as:
Least squares mean · mg/dL
Change From BL to Week 4 in Fasting Plasma Glucose (FPG)
mg/dLMK-0893 + SitagliptinMK-0893 + MetforminSitagliptin + Metformin
Change From BL to Week 4 in Fasting Plasma Glucose (FPG)-73.7 ± 4.4-101.9 ± 4.3-82.8 ± 4.3
Statistical analysis
  • MK-0893 + Sitagliptin vs Sitagliptin + Metformin · Longitudinal Data Analysis · p = 0.050 · Mean difference (final values): 9.1 · 95% CI 0.0 to 18.2
  • MK-0893 + Metformin vs Sitagliptin + Metformin · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): -19.1 · 95% CI -28.0 to -10.1
SecondaryChange From BL to Week 4 in 2-hr Glucose Area Under The Curve (AUC)
Time frame:
BL, 4 weeks (end of double-blind treatment period)
Reported as:
Least squares mean · mg.h/dL
Change From BL to Week 4 in 2-hr Glucose Area Under The Curve (AUC)
mg.h/dLMK-0893 + SitagliptinMK-0893 + MetforminSitagliptin + Metformin
Change From BL to Week 4 in 2-hr Glucose Area Under The Curve (AUC)-187.7 ± 11.4-254.9 ± 11.1-210.3 ± 11.4
Statistical analysis
  • MK-0893 + Sitagliptin vs Sitagliptin + Metformin · Longitudinal Data Analysis · p = 0.056 · Mean difference (final values): 22.6 · 95% CI -0.6 to 45.8
  • MK-0893 + Metformin vs Sitagliptin + Metformin · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): -44.6 · 95% CI -67.3 to -21.8
SecondaryChange From BL to Week 4 in the 2-Hour Total GLP-1 Total AUC

Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone that acts as a potent insulin secretegogue in response to nutrient ingestion and stimulates glucose disposition. The total AUC of Total GLP-1 levels was calculated from blood sample data measured after the morning meal.

Time frame:
BL, 4 weeks (end of double-blind treatment period)
Reported as:
Least squares mean · pmol*h/L
Change From BL to Week 4 in the 2-Hour Total GLP-1 Total AUC
pmol*h/LMK-0893 + SitagliptinMK-0893 + MetforminSitagliptin + Metformin
Change From BL to Week 4 in the 2-Hour Total GLP-1 Total AUC7.4 ± 1.016.4 ± 1.03.2 ± 1.0
Statistical analysis
  • MK-0893 + Sitagliptin vs Sitagliptin + Metformin · Longitudinal Data Analysis · p = 0.001 · Mean difference (final values): 4.2 · 95% CI 1.7 to 6.7
  • MK-0893 + Metformin vs Sitagliptin + Metformin · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): 13.2 · 95% CI 10.7 to 15.7
SecondaryChange From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC

GLP-1 is cleaved from proglucagon to form the active peptide GLP-1. The active form promotes suppression of glucagon secretion. The total AUC of Active GLP-1 levels was calculated from blood sample data measured after the morning meal.

Time frame:
BL, 4 weeks (end of double-blind treatment period)
Reported as:
Least squares mean · pmole*h/L
Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC
pmole*h/LMK-0893 + SitagliptinMK-0893 + MetforminSitagliptin + Metformin
Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC11.0 ± 1.16.3 ± 1.117.6 ± 1.1
Statistical analysis
  • MK-0893 + Sitagliptin vs Sitagliptin + Metformin · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): -6.7 · 95% CI -9.5 to -3.8
  • MK-0893 + Metformin vs Sitagliptin + Metformin · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): -11.3 · 95% CI -14.1 to -8.5

Adverse events

Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-0893 + Sitagliptin—0/48 (0%)7/48 (14.6%)
MK-0893 + Metformin—0/49 (0%)10/49 (20.4%)
Sitagliptin + Metformin—0/49 (0%)8/49 (16.3%)
Most frequent other events
Most frequent other events
EventMK-0893 + SitagliptinMK-0893 + MetforminSitagliptin + Metformin
diarrhoeaGastrointestinal disorders1/486/496/49
upper respiratory tract infectionInfections and infestations4/481/491/49
nauseaGastrointestinal disorders2/484/492/49

Baseline characteristics

Age, Continuous
Age, Continuous(years)MK-0893 + SitagliptinMK-0893 + MetforminSitagliptin + MetforminTotal
Mean53.6 ± 8.052.0 ± 9.753.8 ± 8.753.2 ± 8.8
Gender
Gender(Participants)MK-0893 + SitagliptinMK-0893 + MetforminSitagliptin + MetforminTotal
Female16261557
Male32233489
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2008
First posted
Mar 7, 2008
Start
Feb 2008
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Feb 17, 2012
Last update
Jan 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00631488
Responsible party
Sponsor
First posted
Mar 7, 2008
Start date
Feb 2008
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Feb 17, 2012
Last update
Jan 2, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mk-0893 · Sitagliptin · Metformin

Start the discussion